India: Dr Reddy's to launch Hepatitis C drug in India

NEW DELHI: Dr Reddy's Laboratories today entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

"The company has entered into an agreement with Hetero, under which Dr Reddy's has been licensed to distribute and market Sofosbuvir 400 mg tablets indicated in treatment of chronic Hepatitis C under the brand 'Resof' in India," the Hyderabad-based drug major said in a BSE filing.

Read more at:
http://economictimes.indiatimes.com/articleshow/46664434.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Labels: ,